Clinical Data — Collins Stewart 4th Annual Growth Conference 2008
30 slides from Clinical Data's conference presentation, Jul 9, 2008

Slide 1: Collins Stewart 4th Annual Growth Conference July 9, 2008
1 Collins Stewart 4th Annual Growth Conference July 9, 2008 NASDAQ: CLDA

Slide 2: Forward-Looking Statements
Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Se

Slide 3: Corporate Snapshot
Corporate Snapshot Headquarters Newton, MA NASDAQ CLDA 52 Week Price Range $12.85 to $28.90* Shares Outstanding 21.14M* Market Cap $290.25M* *As of market close on July 07, 2008 5

Slide 4: Our Mission
Our Mission To improve the treatment of disease by commercializing proprietary predictive tests and targeted therapeutics leveraging genetic and other biomarkers that guide therapeutic response and the diagnosis and management of complex clinical conditions 7

Slide 5: Clinical Data - Key Drivers
Clinical Data - Key Drivers Emerging genomics pure play with valuable intellectual property and expertise Proprietary genetic and pharmacogenetic tests Late stage drug candidate - Vilazodone: In Phase 3 of development for the treatment of depression 9

Slide 6: Our Businesses
Our Businesses Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies Proprietary Genetic and Pharmacogenetic Tests 11

Slide 7: Targeted Therapeutic: Vilazodone
13 Targeted Therapeutic: Vilazodone

Slide 8: Vilazodone Profile
Vilazodone Profile: Genetically guided, dual-acting serotonergic in development for the treatment of depression Unique dual mechanism of action: SSRI and 5HT1A partial agonist Status of development Positive results from the first Phase 3 study announced in 2007 In March 2008, initiated second Phase

Slide 9: Vilazodone Phase 3 Study Results
Vilazodone Phase 3 Study Results Achieved statistical significance on primary (MADRS) and related secondary endpoints of efficacy Vilazodone was generally safe and well-tolerated in this study Discontinuations were balanced between vilazodone and placebo The most common treatment-emergent adverse ev

Slide 10: Proprietary Biomarker Identifies 30% of Patients with Higher Response
Proprietary Biomarker Identifies 30% of the Patients with a Higher than Average Response to Vilazodone Least square means of observed MADRS total score by week for Biomarker Vilazodone-treated patients who are marker positive have twice the change in MADRS at week 8 compared to the overall populatio

Slide 11: Vilazodone Development Plan: Milestones
Vilazodone Development Plan: Milestones Second registration Phase 3 study launched March 2008 Study expected to be completed in the first half of 2009 Long-term safety study launched December 2007 Closed enrollment 6 weeks ahead of schedule Manufacture of commercial supply proceeding NDA filing expe

Slide 12: Vilazodone Is A Very Valuable Asset
Vilazodone Is A Very Valuable Asset Vilazodone has been tested in over 1,000 patients and has demonstrated efficacy in the Phase 3 trial Statistical significance in change in MADRS at week 1 No difference between vilazodone and placebo on sexual function as measure by ASEX scale Other side effects w

Slide 13: Genetic and Pharmacogenetic Tests
25 Genetic and Pharmacogenetic Tests

Slide 14: Genetic Testing Landscape
Genetic Testing Landscape Direct-to-consumer Risk for disease Complex diseases with links to treatment Pharmacogenetic tests for drug prescription Examples Marketed by Whole Genome Scans Paternity Nutrition Disease Markers Prostate Cancer Parkinson's Disease Alzheimer's Disease Valuation by Payers L

Slide 15: Expertise and proprietary markers of drug response
Expertise and proprietary markers of drug response Targeted drugs launched with companion pharmacogenetic tests Companion tests launched as companion or combination product Pharmacogenetic tests launched independently of associated drug Foundation Intellectual Property Developing Value Tools for Cli

Slide 16: Genetic Biomarker Intellectual Property
Genetic Biomarker Intellectual Property Diagnosis of complex diseases or syndromes FAMILION LQTS (Long QT Syndrome) Brugada Syndrome Related familial arrhythmogenic disorders Drug receptors FCGAMMA IIIA (IgG1 monoclonal antibodies) VKORC1 (warfarin) ADME genes Transport MDR1, OCT1, MRP1 (chemotherap

Slide 17: FCGR3A and Efficiency of Cell Lysis
FCGR3A Efficient Cell Lysis Inefficient Cell Lysis Dall'Ozzo S, Tartas S, Paintaud G, et al, Cancer Research, 64:4664-4669 FCGR3A 158 V/F or F/F FCGRIIIA Variant Affects Efficiency of Tumor Cell Lysis by IgG1 Mabs IgG1 Mab Tumor Cell 158 V/V NK Cell IgG1 Mab 33

Slide 18: FCGR3A V158F in Response to IgG1 MABs
FCGR3A V158F is Proving Important in Response to IgG1 MABs Response to trastuzumab (Herceptin) in HER2/neu- positive metastatic breast cancer Response to cetuximab (Erbitux) in metastatic colorectal cancer Response to rituximab (Rituxan) monotherapy in follicular lymphoma Response to rituximab in Wa

Slide 19: Genetic and Pharmacogenetic Tests - We Are Delivering
Genetic and Pharmacogenetic Tests - We Are Delivering (1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. (1) Test Long Q/T Cardiology ~100,000 (U.S.) 1/3,000 Disease Incidence/ Prevalence Disease/Therapeutic Area ~2,000

Slide 20: Payer Progress Since Last Update
Progress since last update Approved Medicaid provider in 30 states covering ~29M lives Growing number of BCBS plans: ~65M PPO and ~15M HMO lives covered 15 direct account contracts with key hospital systems Positive coverage policies and contracting increasing with major private payers Payer lives e

Slide 21: millions
millions FY ‘07 FY ‘08 FY ‘09E CLINICAL & DATA A)

Slide 22: The Genomics Services Company
The Genomics Services Company(tm)

Slide 23: Cogenics Overview
Overview High-quality sequencing, gene expression, genotyping and other molecular services worldwide Broad customer base, U.S. and international, including most of the top 20 pharmaceutical companies, Dovetails with next generation genomic testing for diagnostics and targeted drug therapy (companion

Slide 24: Broadest genomics services menu in the industry
Broadest genomics services menu in the industry: Sequencing ABI 3730 Roche 454 GS FLX (new) Genotyping RFLP Mapping Sequenom Luminex Illumina iScanTM System Agilent Microarray aCGH miRNA Affymetrix Microarray Whole Genome Association DNA Analysis DME-T Algynomics Pain Chip Gene Expression Analysis M

Slide 25: Financials
ience Healthcar. Financials

Slide 26: Fiscal 2008 Summary
Fiscal 2008 Summary Revenue from continuing operations was up 20% PGxHealth revenue grew 33%; tests sales grew 41% Cogenics revenue grew 18% Cash burned for the first 9 months was ~$19.0M; $27.0M for the full year; average quarterly burn from operations was ~$7.0M Ramped fourth quarter spending in P

Slide 27: Fiscal Year Revenue Growth
Fiscal Year Revenue Growth $24.4 $20.6 $2.7 $29.4 $24.3 $4.6 FY '07 FY '08 $1.1 $0.5 53

Slide 28: Fiscal Year 2009 Objectives
Fiscal Year 2009 Objectives Advance vilazodone development program with target NDA filing in late 2009 Drive adoption of the Company's proprietary genetic and pharmacogenetic tests Continue to advance priority drug response marker programs and acquire new proprietary markers Identify opportunities w

Slide 29: Clinical Data - Key Drivers
Clinical Data - Key Drivers Emerging genomics pure play Proprietary genetic and pharmacogenetic tests Existing revenue base and pipeline of new tests Growing sales in FAMILION and PGxPredict Late stage drug candidate - Vilazodone Met primary and related secondary end points in first registration tri

Slide 30: Thank You
59 Thank You www.clda.com Investor inquiries: Dahlia Bailey 415-896-5862
Source: SEC EDGAR · 8-K filed Jul 9, 2008
More decks from Clinical Data Inc
J. P. Morgan Healthcare Conference 201127 slides · Jan 12, 2011
Technical Presentation (May 2010)10 slides · May 25, 2010
Rodman & Renshaw Global Investment Conference 200924 slides · Sep 9, 2009
BMO Capital Markets Focus on Healthcare Conference 200930 slides · Aug 5, 2009
Fifth Annual Noble Financial Equity Conference 200923 slides · Jun 9, 2009
Investor Presentation (January 2009)25 slides · Jan 12, 2009